Baidu
map

Biomed Pharmacother: 七氟醚可保护线粒体功能并减轻心肌缺血/再灌注损伤

2020-07-15 “罂粟花”微信号 “罂粟花”微信号

麻醉药物可减轻心肌缺血再灌注(I/R)损伤,而七氟醚和丙泊酚可通过不同分子机制产生心肌保护作用。本研究旨在验证,不同于丙泊酚,七氟醚通过线粒体机制发挥抗I/R损伤的心肌保护作用这一假设。

背景与目的

麻醉药物可减轻心肌缺血再灌注(I/R)损伤,而七氟醚和丙泊酚可通过不同分子机制产生心肌保护作用。本研究旨在验证,不同于丙泊酚,七氟醚通过线粒体机制发挥抗I/R损伤的心肌保护作用这一假设。

方 法

雄性新西兰大白兔(n=42),冠状动脉结扎30min,再灌注3h。戊巴比妥钠诱导麻醉后,吸入七氟醚或静脉注射丙泊酚维持全身麻醉。使用TTC染色法测定心肌梗死面积。分离心肌线粒体并用Clark电极测定线粒体耗氧量。线粒体呼吸链复合体活性(I~IV)采用特异性分析。实验数据用平均值±标准差表示。

结 果

与丙泊酚相比,七氟醚麻醉显着减少了心肌梗死面积(p= 0.0275 vs. 丙泊酚组)。丙泊酚麻醉组线粒体呼吸控制率显着降低(p=0.01909 vs. 假手术组),呼吸链复合体I (p=0.0147 vs. 假手术组;p<0.01 vs.七氟醚组)和复合体IV(p=0.0181 vs. 假手术组)的活性受损。而七氟醚麻醉组并无线粒体功能障碍。此外,七氟醚麻醉组的呼吸链复合体I在I/R损伤期间失活比例明显更高。

结 论

与丙泊酚麻醉相比,七氟醚可保留线粒体呼吸作用,并对I/R损伤产生心肌保护作用。

原始出处:

Lotz C, Stumpner J, Smul TM. Sevoflurane as opposed to propofol anesthesia preserves mitochondrial function and alleviates myocardial ischemia/reperfusion injury.Biomed. Pharmacother. 2020,20:129.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1908598, encodeId=b6e119085987a, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Wed Sep 23 06:57:05 CST 2020, time=2020-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1763600, encodeId=9a861e63600b7, content=<a href='/topic/show?id=8c323064e09' target=_blank style='color:#2F92EE;'>#再灌注损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30647, encryptionId=8c323064e09, topicName=再灌注损伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=56da37541085, createdName=ms9833124466084992, createdTime=Thu Aug 06 15:57:05 CST 2020, time=2020-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996363, encodeId=4a26199636367, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sun May 16 03:57:05 CST 2021, time=2021-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787677, encodeId=70061e876772f, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sat Sep 05 11:57:05 CST 2020, time=2020-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1919098, encodeId=17bf1919098ad, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Dec 27 19:57:05 CST 2020, time=2020-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1677193, encodeId=750616e71933f, content=<a href='/topic/show?id=d31ce7585bb' target=_blank style='color:#2F92EE;'>#线粒体功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77585, encryptionId=d31ce7585bb, topicName=线粒体功能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=92f027457982, createdName=xuruicheng, createdTime=Wed Mar 03 07:57:05 CST 2021, time=2021-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1398011, encodeId=27931398011d0, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoNX3lUOlDKGBUEPNwZx0nibmdcFyeibnX4WMhUSCU2REpGRWtSmnT2CCs0dA5waxvJknYDxwtYnIcQ/132, createdBy=294e2500218, createdName=ms3046638856685384, createdTime=Fri Jul 17 07:57:05 CST 2020, time=2020-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412699, encodeId=61ac141269941, content=<a href='/topic/show?id=1c2f195092d' target=_blank style='color:#2F92EE;'>#七氟醚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19509, encryptionId=1c2f195092d, topicName=七氟醚)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a102881238, createdName=linagood, createdTime=Fri Jul 17 07:57:05 CST 2020, time=2020-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610571, encodeId=9ee416105e1c1, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Jul 17 07:57:05 CST 2020, time=2020-07-17, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1908598, encodeId=b6e119085987a, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Wed Sep 23 06:57:05 CST 2020, time=2020-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1763600, encodeId=9a861e63600b7, content=<a href='/topic/show?id=8c323064e09' target=_blank style='color:#2F92EE;'>#再灌注损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30647, encryptionId=8c323064e09, topicName=再灌注损伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=56da37541085, createdName=ms9833124466084992, createdTime=Thu Aug 06 15:57:05 CST 2020, time=2020-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996363, encodeId=4a26199636367, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sun May 16 03:57:05 CST 2021, time=2021-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787677, encodeId=70061e876772f, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sat Sep 05 11:57:05 CST 2020, time=2020-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1919098, encodeId=17bf1919098ad, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Dec 27 19:57:05 CST 2020, time=2020-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1677193, encodeId=750616e71933f, content=<a href='/topic/show?id=d31ce7585bb' target=_blank style='color:#2F92EE;'>#线粒体功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77585, encryptionId=d31ce7585bb, topicName=线粒体功能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=92f027457982, createdName=xuruicheng, createdTime=Wed Mar 03 07:57:05 CST 2021, time=2021-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1398011, encodeId=27931398011d0, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoNX3lUOlDKGBUEPNwZx0nibmdcFyeibnX4WMhUSCU2REpGRWtSmnT2CCs0dA5waxvJknYDxwtYnIcQ/132, createdBy=294e2500218, createdName=ms3046638856685384, createdTime=Fri Jul 17 07:57:05 CST 2020, time=2020-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412699, encodeId=61ac141269941, content=<a href='/topic/show?id=1c2f195092d' target=_blank style='color:#2F92EE;'>#七氟醚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19509, encryptionId=1c2f195092d, topicName=七氟醚)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a102881238, createdName=linagood, createdTime=Fri Jul 17 07:57:05 CST 2020, time=2020-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610571, encodeId=9ee416105e1c1, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Jul 17 07:57:05 CST 2020, time=2020-07-17, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1908598, encodeId=b6e119085987a, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Wed Sep 23 06:57:05 CST 2020, time=2020-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1763600, encodeId=9a861e63600b7, content=<a href='/topic/show?id=8c323064e09' target=_blank style='color:#2F92EE;'>#再灌注损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30647, encryptionId=8c323064e09, topicName=再灌注损伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=56da37541085, createdName=ms9833124466084992, createdTime=Thu Aug 06 15:57:05 CST 2020, time=2020-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996363, encodeId=4a26199636367, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sun May 16 03:57:05 CST 2021, time=2021-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787677, encodeId=70061e876772f, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sat Sep 05 11:57:05 CST 2020, time=2020-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1919098, encodeId=17bf1919098ad, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Dec 27 19:57:05 CST 2020, time=2020-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1677193, encodeId=750616e71933f, content=<a href='/topic/show?id=d31ce7585bb' target=_blank style='color:#2F92EE;'>#线粒体功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77585, encryptionId=d31ce7585bb, topicName=线粒体功能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=92f027457982, createdName=xuruicheng, createdTime=Wed Mar 03 07:57:05 CST 2021, time=2021-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1398011, encodeId=27931398011d0, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoNX3lUOlDKGBUEPNwZx0nibmdcFyeibnX4WMhUSCU2REpGRWtSmnT2CCs0dA5waxvJknYDxwtYnIcQ/132, createdBy=294e2500218, createdName=ms3046638856685384, createdTime=Fri Jul 17 07:57:05 CST 2020, time=2020-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412699, encodeId=61ac141269941, content=<a href='/topic/show?id=1c2f195092d' target=_blank style='color:#2F92EE;'>#七氟醚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19509, encryptionId=1c2f195092d, topicName=七氟醚)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a102881238, createdName=linagood, createdTime=Fri Jul 17 07:57:05 CST 2020, time=2020-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610571, encodeId=9ee416105e1c1, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Jul 17 07:57:05 CST 2020, time=2020-07-17, status=1, ipAttribution=)]
    2021-05-16 yb6560
  4. [GetPortalCommentsPageByObjectIdResponse(id=1908598, encodeId=b6e119085987a, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Wed Sep 23 06:57:05 CST 2020, time=2020-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1763600, encodeId=9a861e63600b7, content=<a href='/topic/show?id=8c323064e09' target=_blank style='color:#2F92EE;'>#再灌注损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30647, encryptionId=8c323064e09, topicName=再灌注损伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=56da37541085, createdName=ms9833124466084992, createdTime=Thu Aug 06 15:57:05 CST 2020, time=2020-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996363, encodeId=4a26199636367, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sun May 16 03:57:05 CST 2021, time=2021-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787677, encodeId=70061e876772f, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sat Sep 05 11:57:05 CST 2020, time=2020-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1919098, encodeId=17bf1919098ad, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Dec 27 19:57:05 CST 2020, time=2020-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1677193, encodeId=750616e71933f, content=<a href='/topic/show?id=d31ce7585bb' target=_blank style='color:#2F92EE;'>#线粒体功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77585, encryptionId=d31ce7585bb, topicName=线粒体功能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=92f027457982, createdName=xuruicheng, createdTime=Wed Mar 03 07:57:05 CST 2021, time=2021-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1398011, encodeId=27931398011d0, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoNX3lUOlDKGBUEPNwZx0nibmdcFyeibnX4WMhUSCU2REpGRWtSmnT2CCs0dA5waxvJknYDxwtYnIcQ/132, createdBy=294e2500218, createdName=ms3046638856685384, createdTime=Fri Jul 17 07:57:05 CST 2020, time=2020-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412699, encodeId=61ac141269941, content=<a href='/topic/show?id=1c2f195092d' target=_blank style='color:#2F92EE;'>#七氟醚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19509, encryptionId=1c2f195092d, topicName=七氟醚)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a102881238, createdName=linagood, createdTime=Fri Jul 17 07:57:05 CST 2020, time=2020-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610571, encodeId=9ee416105e1c1, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Jul 17 07:57:05 CST 2020, time=2020-07-17, status=1, ipAttribution=)]
    2020-09-05 jj000001
  5. [GetPortalCommentsPageByObjectIdResponse(id=1908598, encodeId=b6e119085987a, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Wed Sep 23 06:57:05 CST 2020, time=2020-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1763600, encodeId=9a861e63600b7, content=<a href='/topic/show?id=8c323064e09' target=_blank style='color:#2F92EE;'>#再灌注损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30647, encryptionId=8c323064e09, topicName=再灌注损伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=56da37541085, createdName=ms9833124466084992, createdTime=Thu Aug 06 15:57:05 CST 2020, time=2020-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996363, encodeId=4a26199636367, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sun May 16 03:57:05 CST 2021, time=2021-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787677, encodeId=70061e876772f, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sat Sep 05 11:57:05 CST 2020, time=2020-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1919098, encodeId=17bf1919098ad, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Dec 27 19:57:05 CST 2020, time=2020-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1677193, encodeId=750616e71933f, content=<a href='/topic/show?id=d31ce7585bb' target=_blank style='color:#2F92EE;'>#线粒体功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77585, encryptionId=d31ce7585bb, topicName=线粒体功能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=92f027457982, createdName=xuruicheng, createdTime=Wed Mar 03 07:57:05 CST 2021, time=2021-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1398011, encodeId=27931398011d0, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoNX3lUOlDKGBUEPNwZx0nibmdcFyeibnX4WMhUSCU2REpGRWtSmnT2CCs0dA5waxvJknYDxwtYnIcQ/132, createdBy=294e2500218, createdName=ms3046638856685384, createdTime=Fri Jul 17 07:57:05 CST 2020, time=2020-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412699, encodeId=61ac141269941, content=<a href='/topic/show?id=1c2f195092d' target=_blank style='color:#2F92EE;'>#七氟醚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19509, encryptionId=1c2f195092d, topicName=七氟醚)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a102881238, createdName=linagood, createdTime=Fri Jul 17 07:57:05 CST 2020, time=2020-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610571, encodeId=9ee416105e1c1, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Jul 17 07:57:05 CST 2020, time=2020-07-17, status=1, ipAttribution=)]
    2020-12-27 sunylz
  6. [GetPortalCommentsPageByObjectIdResponse(id=1908598, encodeId=b6e119085987a, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Wed Sep 23 06:57:05 CST 2020, time=2020-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1763600, encodeId=9a861e63600b7, content=<a href='/topic/show?id=8c323064e09' target=_blank style='color:#2F92EE;'>#再灌注损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30647, encryptionId=8c323064e09, topicName=再灌注损伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=56da37541085, createdName=ms9833124466084992, createdTime=Thu Aug 06 15:57:05 CST 2020, time=2020-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996363, encodeId=4a26199636367, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sun May 16 03:57:05 CST 2021, time=2021-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787677, encodeId=70061e876772f, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sat Sep 05 11:57:05 CST 2020, time=2020-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1919098, encodeId=17bf1919098ad, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Dec 27 19:57:05 CST 2020, time=2020-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1677193, encodeId=750616e71933f, content=<a href='/topic/show?id=d31ce7585bb' target=_blank style='color:#2F92EE;'>#线粒体功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77585, encryptionId=d31ce7585bb, topicName=线粒体功能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=92f027457982, createdName=xuruicheng, createdTime=Wed Mar 03 07:57:05 CST 2021, time=2021-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1398011, encodeId=27931398011d0, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoNX3lUOlDKGBUEPNwZx0nibmdcFyeibnX4WMhUSCU2REpGRWtSmnT2CCs0dA5waxvJknYDxwtYnIcQ/132, createdBy=294e2500218, createdName=ms3046638856685384, createdTime=Fri Jul 17 07:57:05 CST 2020, time=2020-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412699, encodeId=61ac141269941, content=<a href='/topic/show?id=1c2f195092d' target=_blank style='color:#2F92EE;'>#七氟醚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19509, encryptionId=1c2f195092d, topicName=七氟醚)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a102881238, createdName=linagood, createdTime=Fri Jul 17 07:57:05 CST 2020, time=2020-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610571, encodeId=9ee416105e1c1, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Jul 17 07:57:05 CST 2020, time=2020-07-17, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1908598, encodeId=b6e119085987a, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Wed Sep 23 06:57:05 CST 2020, time=2020-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1763600, encodeId=9a861e63600b7, content=<a href='/topic/show?id=8c323064e09' target=_blank style='color:#2F92EE;'>#再灌注损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30647, encryptionId=8c323064e09, topicName=再灌注损伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=56da37541085, createdName=ms9833124466084992, createdTime=Thu Aug 06 15:57:05 CST 2020, time=2020-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996363, encodeId=4a26199636367, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sun May 16 03:57:05 CST 2021, time=2021-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787677, encodeId=70061e876772f, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sat Sep 05 11:57:05 CST 2020, time=2020-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1919098, encodeId=17bf1919098ad, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Dec 27 19:57:05 CST 2020, time=2020-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1677193, encodeId=750616e71933f, content=<a href='/topic/show?id=d31ce7585bb' target=_blank style='color:#2F92EE;'>#线粒体功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77585, encryptionId=d31ce7585bb, topicName=线粒体功能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=92f027457982, createdName=xuruicheng, createdTime=Wed Mar 03 07:57:05 CST 2021, time=2021-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1398011, encodeId=27931398011d0, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoNX3lUOlDKGBUEPNwZx0nibmdcFyeibnX4WMhUSCU2REpGRWtSmnT2CCs0dA5waxvJknYDxwtYnIcQ/132, createdBy=294e2500218, createdName=ms3046638856685384, createdTime=Fri Jul 17 07:57:05 CST 2020, time=2020-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412699, encodeId=61ac141269941, content=<a href='/topic/show?id=1c2f195092d' target=_blank style='color:#2F92EE;'>#七氟醚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19509, encryptionId=1c2f195092d, topicName=七氟醚)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a102881238, createdName=linagood, createdTime=Fri Jul 17 07:57:05 CST 2020, time=2020-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610571, encodeId=9ee416105e1c1, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Jul 17 07:57:05 CST 2020, time=2020-07-17, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1908598, encodeId=b6e119085987a, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Wed Sep 23 06:57:05 CST 2020, time=2020-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1763600, encodeId=9a861e63600b7, content=<a href='/topic/show?id=8c323064e09' target=_blank style='color:#2F92EE;'>#再灌注损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30647, encryptionId=8c323064e09, topicName=再灌注损伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=56da37541085, createdName=ms9833124466084992, createdTime=Thu Aug 06 15:57:05 CST 2020, time=2020-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996363, encodeId=4a26199636367, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sun May 16 03:57:05 CST 2021, time=2021-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787677, encodeId=70061e876772f, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sat Sep 05 11:57:05 CST 2020, time=2020-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1919098, encodeId=17bf1919098ad, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Dec 27 19:57:05 CST 2020, time=2020-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1677193, encodeId=750616e71933f, content=<a href='/topic/show?id=d31ce7585bb' target=_blank style='color:#2F92EE;'>#线粒体功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77585, encryptionId=d31ce7585bb, topicName=线粒体功能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=92f027457982, createdName=xuruicheng, createdTime=Wed Mar 03 07:57:05 CST 2021, time=2021-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1398011, encodeId=27931398011d0, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoNX3lUOlDKGBUEPNwZx0nibmdcFyeibnX4WMhUSCU2REpGRWtSmnT2CCs0dA5waxvJknYDxwtYnIcQ/132, createdBy=294e2500218, createdName=ms3046638856685384, createdTime=Fri Jul 17 07:57:05 CST 2020, time=2020-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412699, encodeId=61ac141269941, content=<a href='/topic/show?id=1c2f195092d' target=_blank style='color:#2F92EE;'>#七氟醚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19509, encryptionId=1c2f195092d, topicName=七氟醚)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a102881238, createdName=linagood, createdTime=Fri Jul 17 07:57:05 CST 2020, time=2020-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610571, encodeId=9ee416105e1c1, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Jul 17 07:57:05 CST 2020, time=2020-07-17, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=1908598, encodeId=b6e119085987a, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Wed Sep 23 06:57:05 CST 2020, time=2020-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1763600, encodeId=9a861e63600b7, content=<a href='/topic/show?id=8c323064e09' target=_blank style='color:#2F92EE;'>#再灌注损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30647, encryptionId=8c323064e09, topicName=再灌注损伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=56da37541085, createdName=ms9833124466084992, createdTime=Thu Aug 06 15:57:05 CST 2020, time=2020-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996363, encodeId=4a26199636367, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sun May 16 03:57:05 CST 2021, time=2021-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787677, encodeId=70061e876772f, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sat Sep 05 11:57:05 CST 2020, time=2020-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1919098, encodeId=17bf1919098ad, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Dec 27 19:57:05 CST 2020, time=2020-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1677193, encodeId=750616e71933f, content=<a href='/topic/show?id=d31ce7585bb' target=_blank style='color:#2F92EE;'>#线粒体功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77585, encryptionId=d31ce7585bb, topicName=线粒体功能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=92f027457982, createdName=xuruicheng, createdTime=Wed Mar 03 07:57:05 CST 2021, time=2021-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1398011, encodeId=27931398011d0, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoNX3lUOlDKGBUEPNwZx0nibmdcFyeibnX4WMhUSCU2REpGRWtSmnT2CCs0dA5waxvJknYDxwtYnIcQ/132, createdBy=294e2500218, createdName=ms3046638856685384, createdTime=Fri Jul 17 07:57:05 CST 2020, time=2020-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412699, encodeId=61ac141269941, content=<a href='/topic/show?id=1c2f195092d' target=_blank style='color:#2F92EE;'>#七氟醚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19509, encryptionId=1c2f195092d, topicName=七氟醚)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a102881238, createdName=linagood, createdTime=Fri Jul 17 07:57:05 CST 2020, time=2020-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610571, encodeId=9ee416105e1c1, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Jul 17 07:57:05 CST 2020, time=2020-07-17, status=1, ipAttribution=)]

相关资讯

Diabetes Care:糖尿病患者和非糖尿病患者心肌缺血负担和预后差异

由此可见,对于TPD>0%的各个水平,甚至0%

Ann Neurol:近期缺血性脑卒中的房颤患者直接口服抗凝剂与维生素K拮抗剂比较

本研究中,我们比较了直接口服抗凝剂(DOACs)和维生素K拮抗剂(VKAs)在房颤(AF)和近期脑缺血患者中的治疗结果。

ST-T改变、T波倒置就是心肌缺血冠心病吗?

临床上遇到心电图T波倒置、ST-T改变,第一印象就是心肌缺血,那么这种心肌缺血表现的心电图就一定是冠心病吗?

NEJM:晚期肾病的患者,出现中重度心肌缺血时,保守治疗还是侵入性治疗?

美国纽约大学格罗斯曼医学院Sripal Bangalore课题组的一项最新研究,探讨了晚期肾病患者冠状动脉疾病的管理策略。相关论文发表在2020年3月30日出版的《新英格兰医学杂志》上。

Circulation:运动过程中MVD与心肌缺血和冠状动脉灌注异常相关

冠状动脉微血管功能障碍(MVD)定义为在存在非阻塞性冠状动脉疾病的情况下,药理性血管扩张药导致血流增加受损。目前,不清楚冠状动脉血管舒张反应减弱与运动生理异常或可诱发的心肌缺血是否相关。

Circulation:冠脉微血管功能障碍与诱发性心肌缺血和冠脉灌注异常相关

冠状动脉微血管功能障碍(MVD)是在存在非阻塞性冠状动脉疾病的情况下,扩血管药物引起的血流增加功能受损。目前尚不清楚冠状动脉扩张剂反应减弱是否与异常运动生理或诱发性心肌缺血有关。招募心绞痛合并非阻塞性冠状动脉疾病的患者,在其休息、仰卧自行车运动和腺苷酸介导的充血期间,用双探头导丝同时测量冠状动脉压力和血流速度。用冠状动脉压力除以血流速度来表示微血管阻力(MR)。如果患者的冠状动脉血流储备<2

Baidu
map
Baidu
map
Baidu
map